Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769079 | 0.80 | MAPT (0.61) | MAPTSMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL24630438 | 0.80 | MAPT (0.61) | MAPTSMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL4468025 | 0.79 | MAPT (0.65) | MAPTSMN1; SMN2GAAATAD2MEN1 | |
| SCHEMBL77700 | 0.79 | ALDH1A1 (0.46) | MAPTSMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL3750305 | 0.79 | MAPT (0.46) | MAPTSMN1; SMN2GAAATAD2MEN1 | |
| SCHEMBL85673 | 0.71 | ALDH1A1 (0.50) | MAPTGAANPC1RAB9APIK3CA | |
| SCHEMBL23064554 | 0.69 | HCAR1 (0.40) | SMN1; SMN2PIK3CAMEN1KMT2AALDH1A1 | |
| SCHEMBL78786 | 0.68 | SMN1; SMN2 (0.45) | MAPTSMN1; SMN2GAANPC1ATAD2 | |
| SCHEMBL76858 | 0.66 | MAPT (0.62) | MAPTSMN1; SMN2GAAPIK3CAMEN1 | |
| SCHEMBL77090 | 0.66 | MAPT (0.47) | MAPTSMN1; SMN2GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-2167499-B1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2167499-B1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| EP-2167499-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008155069-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155069-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, OXA1L, PPOX | MAPT 4810/4885SMN1; SMN2 2496/4885GAA 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.